Literature DB >> 17707834

Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL).

Barbara Eichhorst1, Michael Hallek.   

Abstract

During the past 10 years, significant progress has been achieved in defining new prognostic markers, diagnostic parameters, and treatment options in chronic lymphocytic leukemia (CLL). These developments have led to revision of the National Cancer Institute-sponsored Working Group (NCI-WG) guidelines on CLL established in 1988 and 1996. The update of these guidelines will clarify the role of new prognostic markers in CLL, improve the definitions of response and refractory disease, and add information on the prevention and management of infectious and autoimmune complications.

Entities:  

Mesh：

Year:  2007        PMID： 17707834     DOI： 10.1016/j.beha.2007.02.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN： 1521-6926            Impact factor:   3.020


  4 in total

1.  Flow cytometry and polymerase chain reaction-based analyses of minimal residual disease in chronic lymphocytic leukemia.

Authors:  Sabrina Uhrmacher; Felix Erdfelder; Karl-Anton Kreuzer
Journal:  Adv Hematol       Date:  2010-09-20

2.  MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)?

Authors:  Tait D Shanafelt; Neil E Kay; Tim G Call; Clive S Zent; Diane F Jelinek; Betsy LaPlant; William G Morice; Curtis A Hanson
Journal:  Leuk Res       Date:  2008-01-07       Impact factor: 3.156

3.  Untreated chronic lymphocytic leukemia in Lebanese patients: an observational study using standard karyotyping and FISH.

Authors:  Elie El Rassy; Alain Chebly; Rima Korban; Warde Semaan; Ziad Bakouny; Tarek Assi; Hampig Raphael Kourie; Fadi El Karak; Eliane Chouery; Joseph Kattan
Journal:  Int J Hematol Oncol       Date:  2017-12-21

4.  Dynamic Bayesian networks for prediction of health status and treatment effect in patients with chronic lymphocytic leukemia.

Authors:  Piotr Ladyzynski; Maria Molik; Piotr Foltynski
Journal:  Sci Rep       Date:  2022-02-02       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.